|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study显示文摘AIM: To assess the effects of sitagliptin and nateglinide on lipid metabolism. METHODS: In a parallel group comparative open trial, patients with type 2 diabetes mellitus under treatment at the Japanese Red Cross Medical Center were randomly assigned to receive either sitagliptin (50 mg once daily) or nateglinide (90 mg three times daily before meals). Eligible patients met the following criteria: age ≥ 20 years; hemoglobin A 1c (HbA 1c ) > 6.5% despite diet and exercise; HbA 1c between 6.5% and 8.0%; fasting glucose < 7.77 mmol/L; diet and exercise therapy for more than 3 mo; and ability to read and understand the information for written informed consent. Exclusion criteria were contraindications to sitagliptin, contraindications to nateglinide, pregnancy or possible pregnancy, and severe liver/renal failure. Patients who were considered to be unsuitable by the attending physician for other reasons were also excluded. Blood samples were collected at one and three hours after intake of a test meal. The primary outcome measure was the area under the curve (AUC) of apolipoprotein (Apo) B48 at three hours postprandially. RESULTS: Twenty patients were randomly assigned to the sitagliptin group and sixteen patients were randomized to the nateglinide group. All 36 patients took the medication as directed by the physician in both groups, and they all were analyzed. Apart from antidiabetic drugs, there was no difference between the two groups with respect to the frequency of combined use of lipid-lowering, antihypertensive, and/or antiplatelet drugs. The doses of these medications were maintained during 12 wk of treatment. Detailed dietary advice, together with adequate exercise therapy, was given to the patients so that other factors apart from the two test drugs were similar in the two groups. There were no significant differences of the baseline characteristics between the two groups, except for body mass index (the sitagliptin group: 25.14 ± 3.05 kg/m 2 ; the nateglinide group: 21.39 ± 2.24 kg/m 2 ). Fasting levels of HbA 1c , glycated albumin, 1.5-anhydroglucitol, and blood glucose, as well as the blood glucose levels at one and three hours postprandially, improved in both groups after 12 wk of treatment, and there were no significant differences between the two groups. However, the glucagon level at one hour postprandially (P = 0.040) and the diastolic blood pressure (P<0.01) only showed a significant decrease in the sitagliptin group. In the nateglinide group, there was no significant change in the AUC of Apo B48, the glucagon level at one hour postprandially, the fasting triglyceride level, or the diastolic blood pressure. Body weight was unchanged in both groups. However, the AUC of Apo B48 at three hours postprandially showed a significant decrease in the sitagliptin group from 2.48 ± 0.11 at baseline to 1.94 ± 0.78 g/L per hour after 12 wk (P=0.019). The fasting triglyceride level also decreased significantly in the sitagliptin group (P = 0.035). With regard to lipid-related markers other than Apo B48 and fasting triglycerides, no significant changes were observed with respect to Apo A1, Apo B, or Apo C3 in either group. No adverse events occurred in either group. CONCLUSION: Sitagliptin significantly improves some lipid parameters while having a comparable effect on blood glucose to nateglinide. A large-scale prospective study of sitagliptin therapy is warranted. | Yuichi Kojima Hideyoshi Kaga Shinu Hayashi Toru Kitazawa Yuko Iimura Makoto Ohno Michiyasu Yoshitsugu Mutsunori Fujiwara Toru Hiyoshi | 2013 | World Journal of Diabetes2013，4，1： | 5 |
| 2 | Derivation of rat embryonic stem cells and generation of protease-activated receptor-2 knockout rats显示文摘 | Satoshi Yamamoto Mitsugu Nakata Reiko Sasada Yuki Ooshima Takashi Yano Tadahiro Shinozawa Yasuhiro Tsukimi Michiyasu Takeyama Yoshio Matsumoto Tadatoshi Hashimoto | 2012 | Transgenic Research2012，，4： | 1 |
| 3 | Case study for calculation of factor x ( eco - efficiency) - comparing CRT TV, PDP TV and LCDTV 显示文摘 | Aoe T Michiyasu T Matsuoka Y Shikata N | 2003 | Eco Design Conference2003，，12： | 1 |
| 4 | NR4A nuclear receptors mediate carnitine palmitoyltransferase 1A gene expression by the rexinoid HX600显示文摘 | Michiyasu Ishizawa Hiroyuki Kagechika Makoto Makishima | 2012 | Biochemical and Biophysical Research Communications2012，，4： | 1 |
| 5 | Environmental management accounting for sustainable manufacturing: Establishing mangement system of material flow cost accounting显示文摘 | Nakajima Michiyasu | 2010 | Kansai University Review of Business and Commerce2010，3，12： | 1 |
| 6 | Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors显示文摘Although several previous studies have been published on the effects of dipeptidase-4(DPP-4) inhibitors in diabetic hemodialysis(HD) patients, the findings have yet to be reviewed comprehensively. Eyesight failure caused by diabetic retinopathy and aging-related dementia make multiple daily insulin injections difficult for HD patients. Therefore, we reviewed the effects of DPP-4 inhibitors with a focus on oral antidiabetic drugs as a new treatment strategy in HD patients with diabetes. The following 7 DPP-4 inhibitors are available worldwide: sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin, and saxagliptin. All of these are administered once daily with dose adjustments in HD patients. Four types of oral antidiabetic drugs can be administered for combination oral therapy with DPP-4 inhibitors, including sulfonylureas, meglitinide, thiazolidinediones, and alpha-glucosidase inhibitor. Nine studies examined the antidiabetic effects in HD patients. Treatments decreased hemoglobin A1 c and glycated albumin levels by 0.3% to 1.3% and 1.7% to 4.9%, respectively. The efficacy of DPP-4 inhibitor treatment is high among HD patients, and no patients exhibited significant severe adverse effects such as hypoglycemia and liver dysfunction. DPP-4 inhibitors are key drugs in new treatment strategies for HD patients with diabetes and with limited choices for diabetes treatment. | Yuya Nakamura Hitomi Hasegawa Mayumi Tsuji Yuko Udaka Masatomo Mihara Tatsuo Shimizu Michiyasu Inoue Yoshikazu Goto Hiromichi Gotoh Masahiro Inagaki Katsuji Oguchi | 2015 | World Journal of Diabetes2015，6，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员